Skip to Content

Neupro Now Available in Canada to Treat Parkinson's Disease

NEUPRO® (rotigotine) Now Available in Canada to Treat Parkinson's Disease

TORONTO, Aug. 29, 2013 /CNW/ - UCB Canada Inc. announced today that NEUPRO® (rotigotine) is now available in Canada for the treatment of Parkinson's disease.

The availability of NEUPRO® in Canada follows Health Canada's approval in March, making it the first new treatment for Parkinson's disease approved in Canada in five years.  NEUPRO® is the first and only non-ergolinic dopamine agonist available in a patch, and provides 24-hour delivery of rotigotine through the skin into the blood stream. NEUPRO® has demonstrated efficacy in managing motor symptoms associated with Parkinson's disease.

"As a company committed to bringing meaningful medications to Canadians for serious medical conditions, such as Parkinson's disease, we are very pleased that NEUPRO® is a new option available by prescription from physicians," says  Dr. Gordana Atanackovic, Director, Medical Affairs , UCB Canada Inc.  "Based on clinical evidence and patient experience from numerous countries, we are confident that NEUPRO® can improve quality of life for many Canadians with Parkinson's disease which is very important for people struggling with its disruptive symptoms, such as on-off periods."

About Parkinson's disease

Parkinson's disease (PD) is a chronic, degenerative neurological disease which affects approximately 100,000 Canadians. PD develops with the loss of nerve cells in the brain that produce a chemical called dopamine. The symptoms of PD can have an impact on many dimensions of patients' lives. As dopamine levels fall, movement (motor) symptoms—tremors (uncontrollable shaking), rigidity (stiffness or muscle tensing) and bradykinesia (slowness and loss of spontaneous movement) — can progress, along with the underlying symptoms of PD, which are less well recognized and may be under-treated.

About UCB Canada Inc.

Inspired by patients and driven by science, UCB Canada Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe auto-immune and central nervous system diseases. For more information, please consult

SOURCE UCB Canada Inc.

For further information:

Tamara Macgregor
Weber Shandwick
Tel: 416-642-7914

Robert Tam
UCB Canada Inc.
Tel: 905-287-5128

Posted: August 2013